Drug Trial Radar · NCT00421109
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Last checked: Nov 20, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
522
Actual
Start
Jul 2006
Primary completion
Jul 2007
Study completion Jul 2007
Sponsor
- Lead sponsor
- Faes Farma, S.A.Industry
- Sponsor type
- Industry
- First posted
- Jan 11, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Urticaria.
Conditions
- Urticaria
Interventions
BilastineDrug
Encapsulated 20 mg Tablet. Once daily for 28 days
LevocetirizineDrug
Encapsulated 5 mg tablet. Once daily for 28 days
PlaceboDrug
Encapsulated tablet. Once daily for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline, in the am/pm Total Symptom Score (TSS3), over the 28 days of the treatment period according to the patient's assessment in the diary card. (Reflective Symptoms)Time frame: 28 days
Locations
50 sites in 7 countries. Site status is shown where the registry gives one.
Centre nº 101
Buenos Aires, Argentina
Centre nº 105
Buenos Aires, Argentina
Centre nº 104
Buenos Aires, Argentina
Centre nº 103
Buenos Aires, Argentina
Centre nº 107
Buenos Aires, Argentina
Centre nº 109
Buenos Aires, Argentina
Centre nº 108
Buenos Aires, Argentina
Centre nº 100
Mar Del Plata / Buenos Aires, Argentina
Centre nº 106
Rosario - Santa Fe, Argentina
Centre nº 102
Salta, Argentina
Centre nº 202
Aalst, Belgium
Centre nº 200
Edegem, Belgium
Centre nº 201
Ghent, Belgium
Centre nº 204
Ghent, Belgium
Centre nº 203
Kortrijk, Belgium
Centre nº 302
Lyon, France
Centre nº 305
Marseille, France
Centre nº 307
Nice, France
Centre nº 303
Paris, France
Centre nº 308
Quimper, France
Centre nº 301
Reims, France
Centre nº 411
Berlin, Germany
Centre nº 404
Berlin, Germany
Centre nº 410
Berlin, Germany
Centre nº 400
Hamburg, Germany
Centre nº 407
Hanover, Germany
Centre nº 406
Leipzig, Germany
Centre nº 505
Iwonicz-Zdrój, Poland
Centre nº 507
Krakow, Poland
Centre nº 503
Krakow, Poland
Centre nº 504
Lodz, Poland
Centre nº 502
Lublin, Poland
Centre nº 506
Poznan, Poland
Centre nº 501
Warsaw, Poland
Centre nº 500
Wroclaw, Poland
Centre nº 704
Brasov, Romania
Centre nº 700
Bucharest, Romania
Centre nº 701
Bucharest, Romania
Centre nº 702
Bucharest, Romania
Centre nº 705
Bucharest, Romania
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.